Cargando…

Utilization of genetic information for medicines development and equitable benefit sharing

Advances in genomic research have significantly enhanced modern drug development. However, equitable benefit sharing of the results of scientific advancement has not always been achieved. This paper shows how molecular biology has modified medicines development while also leaving open significant ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Kotone, Kurihara, Chieko, Crawley, Francis P., Kerpel-Fronius, Sandor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300349/
https://www.ncbi.nlm.nih.gov/pubmed/37388927
http://dx.doi.org/10.3389/fgene.2023.1085864
_version_ 1785064568574181376
author Matsuyama, Kotone
Kurihara, Chieko
Crawley, Francis P.
Kerpel-Fronius, Sandor
author_facet Matsuyama, Kotone
Kurihara, Chieko
Crawley, Francis P.
Kerpel-Fronius, Sandor
author_sort Matsuyama, Kotone
collection PubMed
description Advances in genomic research have significantly enhanced modern drug development. However, equitable benefit sharing of the results of scientific advancement has not always been achieved. This paper shows how molecular biology has modified medicines development while also leaving open significant challenges for benefit sharing. Presented here is a conceptual modeling describing the processes in genetic-related medicines development and how these are related to specific ethical considerations. The focus is on three important areas: 1) population genetics and the need for discrimination prevention; 2) pharmacogenomics and the need for inclusive governance; and 3) global health to be achieved in open science frameworks. Benefit sharing is taken as the ethical value that underlies all these aspects. The implementation of benefit sharing requires a value shift in which the outcomes of health science are not viewed simply as trade commodities but also as a “global public good”. This approach should lead to genetic science to contribute to promoting the fundamental human right to health to all members of the global community.
format Online
Article
Text
id pubmed-10300349
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103003492023-06-29 Utilization of genetic information for medicines development and equitable benefit sharing Matsuyama, Kotone Kurihara, Chieko Crawley, Francis P. Kerpel-Fronius, Sandor Front Genet Genetics Advances in genomic research have significantly enhanced modern drug development. However, equitable benefit sharing of the results of scientific advancement has not always been achieved. This paper shows how molecular biology has modified medicines development while also leaving open significant challenges for benefit sharing. Presented here is a conceptual modeling describing the processes in genetic-related medicines development and how these are related to specific ethical considerations. The focus is on three important areas: 1) population genetics and the need for discrimination prevention; 2) pharmacogenomics and the need for inclusive governance; and 3) global health to be achieved in open science frameworks. Benefit sharing is taken as the ethical value that underlies all these aspects. The implementation of benefit sharing requires a value shift in which the outcomes of health science are not viewed simply as trade commodities but also as a “global public good”. This approach should lead to genetic science to contribute to promoting the fundamental human right to health to all members of the global community. Frontiers Media S.A. 2023-06-14 /pmc/articles/PMC10300349/ /pubmed/37388927 http://dx.doi.org/10.3389/fgene.2023.1085864 Text en Copyright © 2023 Matsuyama, Kurihara, Crawley and Kerpel-Fronius. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Matsuyama, Kotone
Kurihara, Chieko
Crawley, Francis P.
Kerpel-Fronius, Sandor
Utilization of genetic information for medicines development and equitable benefit sharing
title Utilization of genetic information for medicines development and equitable benefit sharing
title_full Utilization of genetic information for medicines development and equitable benefit sharing
title_fullStr Utilization of genetic information for medicines development and equitable benefit sharing
title_full_unstemmed Utilization of genetic information for medicines development and equitable benefit sharing
title_short Utilization of genetic information for medicines development and equitable benefit sharing
title_sort utilization of genetic information for medicines development and equitable benefit sharing
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300349/
https://www.ncbi.nlm.nih.gov/pubmed/37388927
http://dx.doi.org/10.3389/fgene.2023.1085864
work_keys_str_mv AT matsuyamakotone utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing
AT kuriharachieko utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing
AT crawleyfrancisp utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing
AT kerpelfroniussandor utilizationofgeneticinformationformedicinesdevelopmentandequitablebenefitsharing